Figure 2.

Knockdown of IRF7 did not inhibit IFN-β-mediated RIG-I and TLR3 induction in BCi-NS1.1 cells. BCi-NS1.1 cells were transfected with IRF7 siRNA for three days (A), or were treated with Ruxolitinib (2 µM), a JAK inhibitor, for 16 h (B). After the siRNA or TSA treatment, the cells were stimulated with 500 U/mL of IFN-β for 6 h. Total RNA was extracted and mRNA expression was assessed by qRT-PCR. Transcript levels of mRNA were normalized relative to the constitutively expressed β-actin gene. Data were expressed as the means ± SEM from three separate experiments. Statistical significance was determined by ANOVA. * denotes significant difference compared to data from IFN-β group, p < 0.05. (C) RIG-I, TLR3 and IRF7 proteins in BCi-NS1.1 cells were detected by immunoblotting. The immunoblot shown is representative of three separate experiments, with quantitation of that result depicted below the image.